Spotlight on ANX007 – Inhibition of C1q for GA

Time: 11:45 am
day: Track 2 Day 1 AM


  • Discuss rationale for chronic classical complement activation as a driver of GA
  • Assess potential advantages of selective, local inhibition of C1q for regulating complement activity in GA
  • Review Phase 1 safety and target engagement with ANX007
  • Provide update on ARCHER, the ongoing Phase 2 study of ANX007 in GA